Therefore, we believe, based on our data that treatment should not only target TLR7/8 and TLR9, but also should target the effect of TLR4 signaling on lupus pathogenesis, and gender differences in other autoimmune diseases. The gene discussed is TLR4; the disease is systemic lupus erythematosus.